Danielle Kamato

List of Publications by Year
in descending order

55 papers	1,965 citations	279798 23 h-index	302126 39 g-index
56 all docs	56 docs citations	56 times ranked	2255 citing authors

#	Article	IF	Citations
1	YYâ€1 1, a camel milkâ€derived peptide, inhibits TGFâ€Î²â€mediated atherogenic signaling in human vascular smooth muscle cells. Journal of Food Biochemistry, 2022, 46, e13882.	2.9	1
2	Akt acts as a switch for GPCR transactivation of the TGFâ€Î² receptor type 1. FEBS Journal, 2022, 289, 2642-2656.	4.7	6
3	Endothelin-1 mediated glycosaminoglycan synthesizing gene expression involves NOX-dependent transactivation of the transforming growth factor-Î² receptor. Molecular and Cellular Biochemistry, 2022, 477, 981-988.	3.1	5
4	Influence of PEGylated porous silicon nanoparticles on permeation and efflux of an orally administered antibiotic. Materials Today Advances, 2022, 13, 100210.	5.2	7
5	Lipopolysaccharide acting via toll-like receptor 4 transactivates the TGF-Î² receptor in vascular smooth muscle cells. Cellular and Molecular Life Sciences, 2022, 79, 121.	5.4	5
6	Endothelinâ€1 dependent expression of <scp>GAG</scp> genes involves <scp>NOX</scp> and p38 mediated Smad linker region phosphorylation. Clinical and Experimental Pharmacology and Physiology, 2022, 49, 710-718.	1.9	2
7	Targeted Molecular Imaging of Cardiovascular Diseases by Iron Oxide Nanoparticles. Arteriosclerosis, Thrombosis, and Vascular Biology, 2021, 41, 601-613.	2.4	44
8	GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential. International Journal of Biological Sciences, 2021, 17, 2050-2068.	6.4	75
9	Impact of sodium glucose cotransporter 2 (SGLT2) inhibitors on atherosclerosis: from pharmacology to pre-clinical and clinical therapeutics. Theranostics, 2021, 11, 4502-4515.	10.0	61
10	Curcumin Inhibits Lysophosphatidic Acid Mediated MCP-1 Expression via Blocking ROCK Signalling. Molecules, 2021, 26, 2320.	3.8	13
11	Endothelial Dysfunction in Atherosclerotic Cardiovascular Diseases and Beyond: From Mechanism to Pharmacotherapies. Pharmacological Reviews, 2021, 73, 924-967.	16.0	359
12	Endothelial Dysfunction and Cardiovascular Disease: History and Analysis of the Clinical Utility of the Relationship. Biomedicines, 2021, 9, 699.	3.2	37
13	Smad linker region phosphorylation is a signalling pathway in its own right and not only a modulator of canonical TGF-Î² signalling. Cellular and Molecular Life Sciences, 2020, 77, 243-251.	5.4	34
14	ROS directly activates transforming growth factor Î² type 1 receptor signalling in human vascular smooth muscle cells. Biochimica Et Biophysica Acta - General Subjects, 2020, 1864, 129463.	2.4	18
15	Artemisinin inhibits glycosaminoglycan chain synthesizing gene expression but not proliferation of human vascular smooth muscle cells. Biochemical and Biophysical Research Communications, 2020, 532, 239-243.	2.1	2
16	Lysophosphatidic acid receptor 5 transactivation of TGFBR1 stimulates the mRNA expression of proteoglycan synthesizing genes XYLT1 and CHST3. Biochimica Et Biophysica Acta - Molecular Cell Research, 2020, 1867, 118848.	4.1	13
17	Toll-like Receptor 4 Stimulates Gene Expression via Smad2 Linker Region Phosphorylation in Vascular Smooth Muscle Cells. ACS Pharmacology and Translational Science, 2020, 3, 524-534.	4.9	12
18	The Role of Toll-like Receptors in Atherothrombotic Cardiovascular Disease. ACS Pharmacology and Translational Science, 2020, 3, 457-471.	4.9	27

#	Article	IF	Citations
19	Smad2 linker region phosphorylation is an autonomous cell signalling pathway: Implications for multiple disease pathologies. Biomedicine and Pharmacotherapy, 2020, 124, 109854.	5.6	15
20	Mechanisms of PAR-1 mediated kinase receptor transactivation: Smad linker region phosphorylation. Journal of Cell Communication and Signaling, 2019, 13, 539-548.	3.4	17
21	Lysophosphatidic acid and its receptors: pharmacology and therapeutic potential in atherosclerosis and vascular disease. , 2019, 204, 107404.		38
22	Treatment of atherosclerotic plaque: perspectives on theranostics. Journal of Pharmacy and Pharmacology, 2019, 71, 1029-1043.	2.4	56
23	Transforming growth factorâ€“Î²1 mediated CHST11 and CHSY1 mRNA expression is ROS dependent in vascular smooth muscle cells. Journal of Cell Communication and Signaling, 2019, 13, 225-233.	3.4	33
24	Targeting epigenetics and non-coding RNAs in atherosclerosis: from mechanisms to therapeutics. , 2019, 196, 15-43.		110
25	Individual Smad2 linker region phosphorylation sites determine the expression of proteoglycan and glycosaminoglycan synthesizing genes. Cellular Signalling, 2019, 53, 365-373.	3.6	20
26	GPCR transactivation signalling in vascular smooth muscle cells: role of NADPH oxidases and reactive oxygen species. Vascular Biology (Bristol, England), 2019, 1, R1-R11.	3.2	13
27	Signalling pathways regulating galactosaminoglycan synthesis and structure in vascular smooth muscle: Implications for lipoprotein binding and atherosclerosis. , 2018, 187, 88-97.		26
28	Flavopiridol Inhibits TGF-Î²-Stimulated Biglycan Synthesis by Blocking Linker Region Phosphorylation and Nuclear Translocation of Smad2. Journal of Pharmacology and Experimental Therapeutics, 2018, 365, 156-164.	2.5	26
29	Thrombin promotes PAI-1 expression and migration in keratinocytes via ERK dependent Smad linker region phosphorylation. Cellular Signalling, 2018, 47, 37-43.	3.6	23
30	G protein coupled receptors can transduce signals through carboxy terminal and linker region phosphorylation of Smad transcription factors. Life Sciences, 2018, 199, 10-15.	4.3	17
31	Endothelial function and dysfunction: Impact of metformin. , 2018, 192, 150-162.		82
32	Activatable magnetic resonance nanosensor as a potential imaging agent for detecting and discriminating thrombosis. Nanoscale, 2018, 10, 15103-15115.	5.6	46
33	Insights into cellular signalling by G protein coupled receptor transactivation of cell surface protein kinase receptors. Journal of Cell Communication and Signaling, 2017, 11, 117-125.	3.4	21
34	Animal models for assessing the impact of natural products on the aetiology and metabolic pathophysiology of Type 2 diabetes. Biomedicine and Pharmacotherapy, 2017, 89, 1242-1251.	5.6	51
35	Gaq proteins: molecular pharmacology and therapeutic potential. Cellular and Molecular Life Sciences, 2017, 74, 1379-1390.	5.4	43
36	RNA sequencing to determine the contribution of kinase receptor transactivation to G protein coupled receptor signalling in vascular smooth muscle cells. PLoS ONE, 2017, 12, e0180842.	2.5	14

#	Article	IF	Citations
37	Multiple Growth Factors, But Not VEGF, Stimulate Glycosaminoglycan Hyperelongation in Retinal Choroidal Endothelial Cells. International Journal of Biological Sciences, 2016, 12, 1041-1051.	6.4	4
38	Integrating the GPCR transactivationâ€dependent and biased signalling paradigms in the context of PAR1 signalling. British Journal of Pharmacology, 2016, 173, 2992-3000.	5.4	12
39	Endothelin-1 (ET-1) stimulates carboxy terminal Smad2 phosphorylation in vascular endothelial cells by a mechanism dependent on ET receptors and de novo protein synthesis. Journal of Pharmacy and Pharmacology, 2016, 69, 66-72.	2.4	18
40	The role of specific Smad linker region phosphorylation in TGF-Î² mediated expression of glycosaminoglycan synthesizing enzymes in vascular smooth muscle. Cellular Signalling, 2016, 28, 956-966.	3.6	41
41	Evaluation of the potential synergism of imatinib-related poly kinase inhibitors using growth factor stimulated proteoglycan synthesis as a model response. Journal of Pharmacy and Pharmacology, 2016, 68, 368-378.	2.4	8
42	Protease activated receptor-1 mediated dual kinase receptor transactivation stimulates the expression of glycosaminoglycan synthesizing genes. Cellular Signalling, 2016, 28, 110-119.	3.6	36
43	Structure, Function, Pharmacology, and Therapeutic Potential of the G Protein, GÃŽÂ±/q,11. Frontiers in Cardiovascular Medicine, 2015, 2, 14.	2.4	53
44	The expansion of GPCR transactivation-dependent signalling to include serine/threonine kinase receptors represents a new cell signalling frontier. Cellular and Molecular Life Sciences, 2015, 72, 799-808.	5.4	37
45	Peptidylâ€prolyl isomerases: Functionality and potential therapeutic targets in cardiovascular disease. Clinical and Experimental Pharmacology and Physiology, 2015, 42, 117-124.	1.9	20
46	25Years of endothelin research: the next generation. Life Sciences, 2014, 118, 77-86.	4.3	8
47	Transforming growth factor Î²-mediated site-specific Smad linker region phosphorylation in vascular endothelial cells. Journal of Pharmacy and Pharmacology, 2014, 66, 1722-1733.	2.4	25
48	Atherogenic, fibrotic and glucose utilising actions of glucokinase activators on vascular endothelium and smooth muscle. Cardiovascular Diabetology, 2014, 13, 80.	6.8	10
49	Assessing the Role of GÎ±q/11 in Cellular Responses: An Analysis of Investigative Tools. Clinical & Experimental Pharmacology, 2014, 04, .	0.3	0
50	Assessing the Role of GÃƒÂŽÃ‚Â±q/11 in Cellular Responses: An Analysis of Investigative Tools. Clinical & Experimental Pharmacology, 2014, 04, .	0.3	0
51	Transforming growth factor-Î² signalling: Role and consequences of Smad linker region phosphorylation. Cellular Signalling, 2013, 25, 2017-2024.	3.6	216
52	Suramin inhibits PDGF-stimulated receptor phosphorylation, proteoglycan synthesis and glycosaminoglycan hyperelongation in human vascular smooth muscle cells. Journal of Pharmacy and Pharmacology, 2013, 65, 1055-1063.	2.4	15
53	Therapeutic implications of endothelin and thrombin G-protein-coupled receptor transactivation of tyrosine and serine/threonine kinase cell surface receptors. Journal of Pharmacy and Pharmacology, 2013, 65, 465-473.	2.4	24
54	(S)-[6]-Gingerol inhibits TGF-Î²-stimulated biglycan synthesis but not glycosaminoglycan hyperelongation in human vascular smooth muscle cells. Journal of Pharmacy and Pharmacology, 2013, 65, 1026-1036.	2.4	35

#	Article	IF	Citations
55	Cell biology of Smad2/3 linker region phosphorylation in vascular smooth muscle. Clinical and Experimental Pharmacology and Physiology, 2012, 39, 661-667.	1.9	31